Atossa Therapeutics(ATOS) Stock Price Today

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Atossa Therapeutics FY 2024 GAAP EPS $(0.20) Beats $(0.22) Estimate, Cash $71.1M
Benzinga08:05 ET
Atossa Therapeutics 2024 Loss/Shr 20c >ATOS
Dow Jones08:01 ET
Earnings Scheduled For March 25, 2025
Benzinga04:32 ET
Here's the Major Earnings Before the Open Tomorrow
Seeking Alpha18:00 ET
ATOSSA GENETICS Earnings Preview: Recent $ATOS Insider Trading, Hedge Fund Activity, and More
Quiver QuantitativeMar 23 17:06 ET
Earnings Week Ahead: LULU, CHWY, DLTR, GME, CSIQ, and More
Seeking AlphaMar 23 08:00 ET

Comments

Teddy123

Mar 11 20:18

Atossa Therapeutics Announces Plans to Pursue Metastatic Breast Cancer Indication for (Z)-Endoxifen and Continued Engagement with FDA on Additional Indications

$Atossa Therapeutics (ATOS.US)$
Breakthrough: New Breast Cancer Drug Shows 3x Better Survival Rate Than Standard Treatment

73844802

Feb 8 00:59

Watch SOUN’s Growth Potential

The breakout for $SoundHound AI (SOUN.US)$ could be imminent. As $Bionano Genomics (BNGO.US)$ moves up in genomics and $Atossa Therapeutics (ATOS.US)$ focuses on therapies, this is one week to keep an eye on!
YouTube

1

Jaguar8

Jan 30 21:18

NEWS

$Atossa Therapeutics (ATOS.US)$
Atossa Therapeutics Responds to PTAB Ruling on U.S. Patent No. 11,572,334 and Announces the Issuance of U.S. Patent No. 12,201,591
Thursday, 30th January at 8:17 am
SEATTLE, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (NASDAQ: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company dedicated to the prevention and treatment of breast cancer, today issued the following statement in response to the Patent Trial and Appeal Boar...

1

Jaguar8

Dec 12, 2024 21:17

NEWS

$Atossa Therapeutics (ATOS.US)$
Atossa Therapeutics to Present Poster Describing the Discovery of Molecules Synergistic with (Z)-endoxifen for the Treatment of Breast Cancer at the 2024 San Antonio Breast Cancer Symposium
Atossa Therapeutics (NASDAQ: ATOS)has announced groundbreaking research findings on compounds that work synergistically with (Z)-endoxifen for breast cancer treatment. The discovery, presented at the 2024 San Antonio Breast Cancer Symposium, utilized both insilico and chemic...

Jaguar8

Dec 11, 2024 21:18

NEWS

$Atossa Therapeutics (ATOS.US)$
Atossa Therapeutics Announces Full Results from Phase 2 KARISMA-Endoxifen Study Demonstrating Statistically Significant Reductions in Mammographic Breast Density
Wednesday, 11th December at 8:15 am
1 MG Dose (Z)-Endoxifen Shows Potential as a Well-Tolerated, Preventative Therapy for Premenopausal Women at Risk of Developing Breast Cancer
Data to be Presented in a Poster Spotlight Session During the 2024 San Antonio Breast Cancer Symposium
SEATTLE, Dec. 11, 202...

ATOS Atossa Therapeutics

Trade Overview

Capital Trend

News

Comments